June 2022

FDA Approves Mounjaro for Type 2 Diabetes
In a press release issued on May 13, 2022, the FDA announced a novel treatment for type 2 diabetes (T2D) using a dually-targeted treatment that was more effective than many current treatments in clinical trials. Mounjaro (tirzepatide) injection was approved for use in adults with T2D in addition to modification in diet and increased exercise. Read more.

Advertisement

Cognitive Impairment Screening in Patients With T2D Improves Outcomes 
According to new research, individuals may be at higher risk of heart attack, stroke, and death if they have cognitive impairment in addition to type 2 diabetes (T2D). See what researchers are saying about this interesting confounding relationship that may suggest cognitive function could predict a person's future risk of heart disease and death. Read more.

Advertisement

Insulin Resistance Considered a Breast Cancer Risk Factor
A recent study from researchers at the University of California San Diego School of Medicine builds on earlier epidemiological studies already hinting at an associated risk of dysfunctional glucose metabolism in patients with breast cancer. Learn more about insulin resistance and why it is considered a risk factor for breast cancer and poor prognosis for survival in those diagnosed with the disease.

Advertisement
Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App